Get the Stockscreener App
2.48
1.64%
0.04
AIM ImmunoTech Inc stock is traded at $2.48, with a volume of 50,326.
It is up +1.64% in the last 24 hours and down -15.07% over the past month.
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen, a drug of macromolecular ribonucleic acid molecule for the treatment of chronic fatigue syndrome. It is also developing Ampligen for the treatment of Hepatitis B and HIV, as well as patients with renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, urothelial, prostate, and pancreatic cancer. AIM ImmunoTech Inc. has agreements with UMN Pharma Inc., Japan National Institute of Infectious Diseases, and Shionogi & Co., Ltd. for the evaluation and discussion of business relationships concerning a COVID-19 therapeutic and vaccine. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was founded in 1966 and is headquartered in Ocala, Florida.
See More
Previous Close:
$2.44
Open:
$2.52
24h Volume:
50,326
Relative Volume:
0.22
Market Cap:
$6.72M
Revenue:
$202.00K
Net Income/Loss:
$-28.96M
P/E Ratio:
-4.1333
EPS:
-0.6
Net Cash Flow:
$-21.85M
1W Performance:
+1.22%
1M Performance:
-15.07%
6M Performance:
+1,786%
1Y Performance:
+649.02%
1-Day Range:
$2.4209
$2.5537
1-Week Range:
$2.35
$2.5537
52-Week Range:
$0.0633
$20.35
AIM ImmunoTech Inc Stock (AIM) Company Profile
Name
AIM ImmunoTech Inc
Sector
Industry
Phone
352 448 7797
Address
2117 SW Highway 484, Ocala, FL
Compare AIM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AIM
AIM ImmunoTech Inc
|
2.48 | 6.61M | 202.00K | -28.96M | -21.85M | -0.60 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.12 | 101.77B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.38 | 60.12B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
452.00 | 59.45B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
750.78 | 44.90B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
341.80 | 35.07B | 3.81B | -644.79M | -669.77M | -6.24 |
AIM ImmunoTech Inc Stock (AIM) Latest News
AIM ImmunoTech receives NYSE American notice of delisting and appeal - MSN
AIM ImmunoTech reports Q2 EPS ($3.68) vs ($3.00) last year - MSN
AIM ImmunoTech Highlights Growing Body of Compelling Data - GlobeNewswire
AIM ImmunoTech Highlights Growing Body of Compelling Data of Ampligen for the Treatment of Pancreatic Cancer at Conference in Poland | AIM Stock News - GuruFocus
AIM ImmunoTech Reports Positive Data on Ampligen for Pancreatic Cancer Treatment - AInvest
Breakthrough in Late-Stage Pancreatic Cancer: AIM's Ampligen Shows Survival Benefits in Phase 2 Trial - Stock Titan
AIM ImmunoTech Files Definitive Proxy Statement and Sends Letter to Shareholders - Quantisnow
AIM ImmunoTech releases CEO Corner segment - MSN
AIM ImmunoTech Releases CEO Corner Segment, Discusses Recent Progress with Ampligen - AInvest
AIM ImmunoTech Announces CEO Corner Segment Release - AInvest
AIM ImmunoTech Announces Release of the Next CEO Corner Segment - GlobeNewswire
Biotech AIM ImmunoTech's CEO Details Progress of Promising Pancreatic Cancer Drug Ampligen in Latest Update - Stock Titan
AIM ImmunoTech's Oncology Gambit: Can Pancreatic Cancer Breakthroughs and Financial Stability Fuel a Biotech Comeback? - AInvest
AIM ImmunoTech Reports Q2 Losses Amid Ongoing Trials, Revenue Down to $25k. - AInvest
AIM ImmunoTech Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
Promising Pancreatic Cancer Treatment: AIM ImmunoTech's Ampligen Shows Strong Safety Data in Phase 2 - Stock Titan
Webull Corporation shares rise 1.49% premarket after AIM ImmunoTech and Moleculin Biotech to present at Webull Financial Corporate Connect Webinar Series. - AInvest
AIM ImmunoTech Reports Increased Losses Amid Ongoing Trials - TipRanks
AIM ImmunoTech to present at Webull Financial Corporate Connect webinar. - AInvest
AIM ImmunoTech CEO to Share Company Updates at Webull's Biotech Investment Series - Stock Titan
AIM ImmunoTech to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech - GlobeNewswire
AIM ImmunoTech Presents at Webull Financial Corporate Connect Webinar Series: Biotech/MedTech. - AInvest
AIM ImmunoTech Announces Pricing of $8.0 Million Public Offering - 富途牛牛
AIM ImmunoTech’s Oncology Drug Ampligen to Be Featured in - GlobeNewswire
AIM ImmunoTech's Oncology Drug Ampligen to Be Featured in Key Pr - GuruFocus
Breakthrough: New Cancer Drug Ampligen Delivers Promising Results in Pancreatic, Ovarian, and Breast Cancer Trials - Stock Titan
AIM ImmunoTech’s Oncology Drug Ampligen to Be Featured in Key Presentations and Abstract at the International 5th Annual Marie Skłodowska-Curie Symposium on Cancer Research and Care (MSCI MSCS-2025) - The Manila Times
AIM ImmunoTech (AIM) Advances Clinical Trials and Strengthens Financial Position - GuruFocus
AIM ImmunoTech Builds Positive Momentum and Reiterates Focus on - GuruFocus
AIM ImmunoTech Builds Positive Momentum and Reiterates Focus on Driving Ampligen® Clinical Development Toward Pancreatic Cancer Approval | AIM Stock News - GuruFocus
AIM ImmunoTech Builds Positive Momentum and Reiterates - GlobeNewswire
Breakthrough in Pancreatic Cancer Treatment: AIM's Ampligen-Imfinzi Combo Shows Positive Survival Data - Stock Titan
AIM ImmunoTech Surges Amid Key Developments, Raises $8 Million in Public Offering - AInvest
AIM ImmunoTech Closes $8 Million Public Offering - The Globe and Mail
Latest News - Asia Food Journal
AIM ImmunoTech Announces Closing of $8.0 Million Public Offering - GlobeNewswire
AIM ImmunoTech's $8.0M Capital Raise: A Strategic Move to Fuel Ampligen's Clinical Progress and Investor Value? - AInvest
AIM ImmunoTech closes public offering, raises $8 mln. - AInvest
AIM ImmunoTech Secures $8M Funding: New Shares at $4.00 Plus 5-Year Warrants - Stock Titan
AIM ImmunoTech reports Ampligen combo trial data for pancreatic cancer - MSN
Biotech Alert: Searches spiking for these stocks today - TipRanks
AIM ImmunoTech's Stock Falls 50% Following $8M Securities Offering - AInvest
Evaluating AIM ImmunoTech's Capital Raise: A Strategic Crossroads for Investors - AInvest
AIM Shares Fall After Pricing of $8 Million Public Offering - MarketScreener
Crude Oil Gains Over 1%; UnitedHealth Earnings Miss Views - Benzinga
AIM ImmunoTech stock plunges after pricing $8 million public offering By Investing.com - Investing.com Australia
AIM ImmunoTech stock plunges after pricing $8 million public offering - Investing.com
AIM ImmunoTech Inc Stock (AIM) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.40%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):